HonorHealth
VC Fund
Scottsdale, United States
HonorHealth is a VC fund in Scottsdale focused on Health Care and Medical Device. HonorHealth represent integrity & honesty and honor your right to personalized, easy-to-navigate healthcare.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries HonorHealth invests in
Stages HonorHealth invests in
Countries HonorHealth invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jeffrey Becker
|
|||
Todd LaPorte
|
|||
Investment Focus
Industry
- Health Care 4 (57%)
- Medical Device 3 (43%)
- Medical 2 (29%)
- Health Diagnostics 2 (29%)
- Sports 1 (14%)
Stage
- Seed 2 (29%)
- Series A 2 (29%)
- Series D 1 (14%)
- Funding Round 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jeffrey Becker
Staff Neurohospitalist
|
Staff Neurohospitalist | Total investments: 0 | Find email | |
|
Todd LaPorte
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CND Life Sciences
|
CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $13.5M / Series A / May 01, 2025 | |
Qventus
|
Qventus optimizes operational decisions in hospitals in real time. They use machine learning and optimization algorithms to help hospitals reduce costs, improve quality and experience of the healthcare they deliver.Qventus is a YCombinator and StartX company working with some of the top health institutions in the country to change how healthcareis run. | $85M / Series D / Jan 13, 2025 | |
Altoida
|
Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR),and artificial intelligence (AI).Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt. | $14M / Series A / Mar 30, 2022 | |
|
CND Life Sciences
|
CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $5M / Seed / Feb 01, 2022 | |
CenSyn
|
CenSyn is a brain health screening platform. They create a handheld EEG monitoring device for accelerated screening of Alzheimer's, traumatic brain injury, and epilepsy. They make brain health screening and monitoring more accessible to diverse patient populations. | Seed / Jun 10, 2021 | |
|
CND Life Sciences
|
CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $2.4M / Seed / Jan 19, 2021 | |
NeoLight
|
Neolight is a medical device company that develops phototherapy beds to cure jaundice in pre-term and full-term babies. Its product range consists of Skylife and hypothermia treatment. Skylife offers phototherapy treatment for newborns. NeoLight distributes a device that provides hypothermia treatment to infants with low birth weight. | $7M / Oct 27, 2020 |
Co-Investors
Bessemer Venture Partners
2 deals together
Cambrian Capital Partners
2 deals together
1517 Fund
1 deal together
Allina Health
1 deal together
Alpana Ventures
1 deal together
Berkeley SkyDeck Fund
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does HonorHealth invest in?
HonorHealth invests primarily in Health Care, Medical Device and Medical startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact HonorHealth?
Public channels for HonorHealth include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at HonorHealth?
The team at HonorHealth includes Jeffrey Becker (Staff Neurohospitalist) and Todd LaPorte (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
